TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today roundup published Oct. 13, 2026, covered developments in cardiovascular medicine, including FDA clearance of BridgeSource’s SmartRead implant identification system and research on county-level variation in CVD survival. New York state Sen. James Tedisco also urged Gov. Kathy Hochul to address a dispute between Ellis Medicine and St. Peter’s Healthcare that he says could affect about 50,000 cardiology patients. The report does not provide details on the system’s use, the county study’s findings, or the lawsuit’s status.
A MedPage Today cardiovascular roundup published Oct. 13 reported that the FDA cleared BridgeSource’s SmartRead system to identify cardiac implants by brand, while also highlighting research on county-level gaps in cardiovascular disease survival and a New York senator’s appeal to Gov. Kathy Hochul over a hospital dispute. The items point to developments in device identification, uneven health outcomes and patient access, though the roundup offers limited detail on each.
The report said the FDA cleared BridgeSource’s SmartRead system for identifying cardiac implants by brand. It did not describe how the system works, which implant types it covers, or when or where it will be available. The clearance was reported by Mass Device, as cited in the roundup.
Separately, research published in the Journal of the American College of Cardiology found that cardiovascular disease survival in the United States continues to improve, while substantial variation remains from county to county. The roundup said that variation can exceed differences between states. It did not include specific county figures or explain which factors account for the gaps.
In New York, state Sen. James Tedisco called on Gov. Kathy Hochul to act in a dispute between Ellis Medicine and St. Peter’s Healthcare involving noncompete agreements. Tedisco said litigation could leave 50,000 cardiology patients at risk of losing access to their doctors. That figure and the projected effect were presented as Tedisco’s claim; the roundup did not report an independent estimate or a response from the hospitals or governor.
Access, Outcomes and Device Identification
The three developments touch different parts of cardiovascular care. A system that identifies cardiac implants by brand may help people and clinicians establish what device a patient has, although the source does not explain its intended users or practical benefits. The FDA clearance is confirmed in the roundup, but details needed to judge the system’s reach are not provided.
The county findings underline that national improvement in CVD survival does not mean outcomes are even everywhere. Local differences can be obscured by state averages, making county-level data relevant to understanding where care or health outcomes may lag. The report gives no county rankings or causes, so it cannot show which communities are most affected.
The New York dispute raises a more immediate access concern, but its scale remains a senator’s estimate. If the litigation affects physician relationships, patients could face disruption; the roundup does not establish that access has already been lost or that the 50,000 patients will be affected.
cardiac implant identification system
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The Three Developments in Brief
The items appeared in a short roundup of recent cardiovascular developments by Nicole Lou, a senior staff writer at MedPage Today. The report also summarized research and announcements on cholesterol trends, transplant prioritization, blood pressure, pregnancy-related cardiovascular risks and other topics. Those additional items are not described here because the report’s headline centers on implant identification, CVD differences by county and the New York cardiology dispute.
According to the roundup, researchers reviewing National Health and Nutrition Examination Survey data from 1999 to 2023 observed improved LDL cholesterol among young people without atherosclerotic CVD. It also cited European guidance on advising patients about extreme heat and heart health, and registry-based modeling of a proposed U.S. Candidate Risk Score for adult heart transplant candidates. These were separate findings and announcements, not details about the SmartRead system or the New York litigation.
The hospital issue involves Ellis Medicine and St. Peter’s Healthcare and litigation over noncompete agreements, according to the report. It does not lay out the legal claims, the agreements’ terms, or the hospitals’ positions. The matter should therefore be understood as an ongoing dispute rather than a settled change in patient access.
“50,000 cardiology patients”
— New York state Sen. James Tedisco, as reported by MedPage Today
brand-specific cardiac implant scanner
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Details Still Missing From the Report
The roundup does not give the FDA’s clearance documentation, SmartRead’s technical specifications, the implant brands or categories it can identify, or the settings in which it may be used. It is also unclear whether clearance will lead to immediate availability.
For the county research, the report supplies no effect sizes, county names, study methods or explanations for the variation. The broad finding is that survival has improved nationally while local differences remain; the size and sources of those differences cannot be established from the roundup alone.
For the New York dispute, the legal status, any court decisions, the hospitals’ responses and the governor’s position were not included. It is also unclear how many patients, if any, have experienced changes in care. Tedisco’s concern about 50,000 patients is attributed to him, not reported as a confirmed impact.
cardiology device management tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Clearance, Research and Lawsuit Updates
Further information from BridgeSource or the FDA would clarify the SmartRead system’s capabilities, intended use and availability. The county-level study itself would be needed to identify the locations and factors behind the reported survival differences.
In New York, the next developments depend on the litigation and any response from Ellis Medicine, St. Peter’s Healthcare or Gov. Hochul. The roundup does not state whether the governor has acted, whether the hospitals are negotiating, or when a court or policy decision may come. Until those details emerge, the reported risk to patient access remains a concern raised by Tedisco rather than a confirmed outcome.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA clear?
The roundup reported FDA clearance for BridgeSource’s SmartRead system, described as a system for identifying cardiac implants by brand. It did not provide technical or availability details.
What did researchers report about CVD survival?
The cited research found that U.S. cardiovascular disease survival has continued to improve, while county-level variation remains and may be greater than differences between states. The roundup did not identify specific counties or give numerical estimates.
Why did Sen. James Tedisco ask Gov. Hochul to act?
Tedisco urged the governor to address litigation between Ellis Medicine and St. Peter’s Healthcare over noncompete agreements. He said about 50,000 cardiology patients could lose access to their doctors; that potential impact was not independently confirmed in the roundup.
Have patients already lost access to their cardiologists?
The report does not say that patients have already lost access. It describes a possible effect raised by Tedisco while the dispute is in litigation.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
